UiPath (PATH)
(Delayed Data from NYSE)
$12.00 USD
-0.25 (-2.04%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $11.98 -0.02 (-0.17%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth C Momentum B VGM
Brokerage Reports
0 items in cart
[PATH]
Reports for Purchase
Showing records 121 - 129 ( 129 total )
Industry: Medical - Products
LIFE SCIENCES: 2012 Life Sciences and Healthcare Preview: Macro and Sector Trends; Catalysts; Top Picks
Provider: WEDBUSH SECURITIES INC.
Analyst: JAMES S
Industry: Medical - Products
Q3 Financials Were Uneventful and Cash Runway Extends Past NDA Resubmission In H1:12.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Products
Industry: Medical - Products
Results From Second 12 Month Safety Trial Confirm Favorable Safety Profile for Zelrix Treatment of Migraines. Reiterate OUTPERFORM.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Products
We Estimate Zelrix Approval Delayed by About Six Months. Reiterate OUTPERFORM But Reducing Fair Value to $17 for Delay
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Products
Industry: Medical - Products
Q2 Financials Were Uneventful But Cash Runway Is Projected Through Major Near-Term Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Products
Initiating Coverage with an OUTPERFORM Rating and Fair Value of $20: Novel Drug Delivery for Better Patient Compliance.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Products
ValuEngine Detailed Valuation Report for PATH
Provider: VALUENGINE, INC